Changes in Lognormal Shape Parameter Guide Design of Patient-Specific Radiochemotherapy Cocktails
Open Access
- 18 March 2011
- journal article
- Published by Society of Nuclear Medicine in Journal of Nuclear Medicine
- Vol. 52 (4) , 642-649
Abstract
Uptake of radiopharmaceuticals and chemotherapeutic drugs is nonuniform at the microscopic level. Their distributions are typically lognormal, suggesting that failure in chemotherapy and targeted radionuclide therapy may be attributable, in part, to the characteristics of this biologically ubiquitous distribution. The lognormal problem can be overcome by using cocktails of 2 or more agents, tailored such that at least 1 agent is strongly incorporated by every cell in the target population. Therefore, critical assessment of the tissue uptake of each cocktail component is warranted. Methods: Cellular incorporation of the α-particle–emitting radiochemical (210Po-citrate) and 2 anticancer drugs (daunomycin and doxorubicin) was determined using flow cytometry. The role of their lognormal distribution in clonogenic cell survival was evaluated. Results: The shape parameter of the lognormal distribution was found to be correlated to both intracellular agent concentration and cell survival. Although no difference emerged between the shape parameters for citrate within the first 2 logs of cell kill, those for daunomycin and doxorubicin changed significantly. Conclusion: Changes in the value of the lognormal shape parameter and slope of the cellular drug uptake curves can be used to rapidly screen radiopharmaceuticals and other cytotoxic agents to formulate more effective cocktails for cancer therapy.Keywords
This publication has 30 references indexed in Scilit:
- Modulation of the sensitivity in Chinese hamster cells to photons and fast neutrons by cisplatin, vinblastine, and bleomycinCanadian Journal of Physiology and Pharmacology, 2009
- Multimodality Therapy: Potentiation of High Linear Energy Transfer Radiation with Paclitaxel for the Treatment of Disseminated Peritoneal DiseaseClinical Cancer Research, 2008
- Lognormal Distribution of Cellular Uptake of Radioactivity: Statistical Analysis of α-Particle Track AutoradiographyJournal of Nuclear Medicine, 2008
- Modulation of radiosensitivity in Chinese hamster lung fibroblasts by cisplatinCanadian Journal of Physiology and Pharmacology, 2008
- Biological Response to Nonuniform Distributions of210Po in Multicellular ClustersRadiation Research, 2007
- Induction cisplatin-gemcitabine-paclitaxel plus concurrent radiotherapy and gemcitabine in the multimodality treatment of unresectable stage IIIB non-small cell lung cancerLung Cancer, 2006
- Challenges and progress in predicting biological responses to incorporated radioactivityRadiation Protection Dosimetry, 2006
- Gemcitabine and cisplatin in a concomitant alternating chemoradiotherapy program for locally advanced head-and-neck cancer: A pharmacology-guided scheduleInternational Journal of Radiation Oncology - Biology - Physics (IJROBP), 2006
- Fluorescent Imaging of Citrate and Other Intermediates in the Citric Acid CycleAngewandte Chemie International Edition, 2004
- Combined Modality Radioimmunotherapy with Taxol and 90 Y-LYM-1 for Raji Lymphoma XenograftsCancer Biotherapy and Radiopharmaceuticals, 1998